Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825176 | 0.80 | CYP2C19 (0.50) | CYP2C19 | |
| SCHEMBL873448 | 0.80 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL29352013 | 0.80 | SLC6A4 (0.33) | CYP2C19 | |
| SCHEMBL2419343 | 0.80 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL11741874 | 0.78 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL9010882 | 0.78 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL11741871 | 0.78 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL11741880 | 0.78 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL27670649 | 0.77 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL9010958 | 0.76 | CYP4F2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321164-A2 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | ViiV Healthcare UK (No.5) Limited (GB) | 2024-02-14 | — | — | EP | disclosed |
| EP-3784349-B1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-12-27 | — | — | EP | disclosed |
| US-20230192758-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK (No.5) Limited (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | CYP2C19 226/4885 |
| US-20230192758-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | OGFRL1, ZC3HAV1L, CD4 | CYP2C19 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.